Akarna Therapeutics (US & UK) just raised $15M (€13M) in a series B round led by Forbion Partners – one of the leading VCs from Europe.
Also run by existing New York investors New Science Ventures and Third Point, the round purpose was to raise funding to develop a new drug for the liver disease Non-alcoholic steatohepatitis (NASH).
I had a chat with Marco Boorsma, a partner at Forbion (which is based in the Netherlands), to better understand why they did this investment and why now.
So, what’s your feeling on NASH?
NASH should be a really big indication in the future (it already affects 30 million patients worldwide) and as such, a potential billion euro market. Essentially NASH is related to our Western-style of living and is closely linked to diabetes and obesity. And as both are growing in our western society, NASH should grow as well.
The most surprising in this disease is that there is no drug approved yet.